Krishnan Ramaswamy

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha et al. · New England Journal of Medicine · 2016 · 757 citations

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Bertrand Tombal, Fred Saad, David F. Penson et al. · The Lancet Oncology · 2019 · 105 citations · Full text

Urology, Patient-reported Outcomes, Medicine +8

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang et al. · Prostate Cancer and Prostatic Diseases · 2021 · 57 citations · Full text

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi et al. · European Urology · 2020 · 52 citations · Full text

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial

Michael Staehler, Robert J. Motzer, Daniel J. George et al. · Annals of Oncology · 2018 · 48 citations · Full text